Recent Progress in Carrier-Free Nanomedicine for Tumor Phototherapy

Adv Healthc Mater. 2023 Feb;12(4):e2202307. doi: 10.1002/adhm.202202307. Epub 2022 Nov 24.

Abstract

Safe and effective strategies are urgently needed to fight against the life-threatening diseases of various cancers. However, traditional therapeutic modalities, such as radiotherapy, chemotherapy and surgery, exhibit suboptimal efficacy for malignant tumors owing to the serious side effects, drug resistance and even relapse. Phototherapies, including photodynamic therapy (PDT) and photothermal therapy (PTT), are emerging therapeutic strategies for localized tumor inhibition, which can produce a large amount of reactive oxygen species (ROS) or elevate the temperature to initiate cell death by non-invasive irradiation. In consideration of the poor bioavailability of phototherapy agents (PTAs), lots of drug delivery systems have been developed to enhance the tumor targeted delivery. Nevertheless, the carriers of drug delivery systems inevitably bring biosafety concerns on account of their metabolism, degradation, and accumulation. Of note, carrier-free nanomedicine attracts great attention for clinical translation with synergistic antitumor effect, which is characterized by high drug loading, simplified synthetic method and good biocompatibility. In this review, the latest advances of phototherapy with various carrier-free nanomedicines are summarized, which may provide a new paradigm for the future development of nanomedicine and tumor precision therapy.

Keywords: carrier-free nanomedicines; self-assembly; tumor phototherapy.

Publication types

  • Review

MeSH terms

  • Cell Line, Tumor
  • Drug Delivery Systems
  • Humans
  • Nanomedicine
  • Neoplasms* / drug therapy
  • Photochemotherapy*
  • Phototherapy
  • Theranostic Nanomedicine